FDA 483 - Cadila Pharmaceuticals Limited - January 20, 2023

An FDA inspection of Cadila Pharmaceuticals Limited in Ankleshwar, Gujarat, India, revealed a significant issue with laboratory controls. The firm failed to establish the sensitivity of test methods, specifically regarding the determination of chromatographic purity for intermediates. This indicates a deficiency in ensuring the accuracy and reliability of analytical testing procedures.